| Literature DB >> 23317154 |
Abhik Seal1, Perumal Yogeeswari, Dharmaranjan Sriram, David J Wild.
Abstract
BACKGROUND: Mycobacterium tuberculosis encodes 11 putative serine-threonine proteins Kinases (STPK) which regulates transcription, cell development and interaction with the host cells. From the 11 STPKs three kinases namely PknA, PknB and PknG have been related to the mycobacterial growth. From previous studies it has been observed that PknB is essential for mycobacterial growth and expressed during log phase of the growth and phosphorylates substrates involved in peptidoglycan biosynthesis. In recent years many high affinity inhibitors are reported for PknB. Previously implementation of data fusion has shown effective enrichment of active compounds in both structure and ligand based approaches .In this study we have used three types of data fusion ranking algorithms on the PknB dataset namely, sum rank, sum score and reciprocal rank. We have identified reciprocal rank algorithm is capable enough to select compounds earlier in a virtual screening process. We have also screened the Asinex database with reciprocal rank algorithm to identify possible inhibitors for PknB.Entities:
Year: 2013 PMID: 23317154 PMCID: PMC3600029 DOI: 10.1186/1758-2946-5-2
Source DB: PubMed Journal: J Cheminform ISSN: 1758-2946 Impact factor: 5.514
Figure 1Some of the PknB inhibitors stsructures with IC50 values.
Figure 2Shows the different pharmacohores developed by Phase E-pharmacophore.
Figure 3The picture represents the E-pharmacophore generated for Mitoxantrone.
The table shows the enrichment factors, BEDROC value and RIE of the different methods applied in virtual screening
| E-pharmacophore I(5 sites) | 12 | 11 | 10.51 | 6.8 | 0.538 | 7.81 |
| E-pharmacophore II(7 sites) | 30 | 30 | 13 | 6.8 | 0.729 | 10.6 |
| E-pharmacophore III(5 sites) | 30 | 27 | 13 | 6.5 | 0.706 | 10.26 |
| ROCS | 30 | 27 | 13.14 | 7.42 | 0.749 | 10.89 |
| Glide XP | 27 | 21 | 11.42 | 6.28 | 0.629 | 9.14 |
| Sum score | 30 | 29 | 7.42 | |||
| Sum rank | 30 | 24 | 12 | 7.42 | 0.703 | 10.21 |
| Reciprocal rank | 30 | 30 | 8.85 |
Shows the % yield of actives (Ya), %actives, sensitivity, specificity and GH score of pharmacophores
| E- pharmacophore I | 7 | 68 | 0.68 | 0.71 | 0.157975 |
| E- pharmacophore II | 6 | 74.2 | 0.742 | 0.596 | 0.137378 |
| E- pharmacophore III | 65.7 | 0.657 |
Shows donor D8 and Ring R13 along with any other pharmcophoric point from 5 sites
| D8,R12,R13 | 0.331 | 4.81 | 7.3 | 51.4 | 0.774 | 0.1418355 |
| D8,R13,R11 | 0.306 | 4.45 | 11.11 | 31.4 | 0.912 | 0.1475844 |
| D8,R13,A4 | 0.183 | 2.67 | 5.8 | 14.2 | 0.919 | 0.072601 |
| D8,R13,D5 | 0.32 | 4.74 | 11.8 | 31.4 | 0.918 | 0.153306 |
| D8,D6,R13 | 0.18 | 2.72 | 23.8 | 14.2 | 0.984 | 0.210576 |
This indicates that D8 and R13 cannot be selected as a pharmacophoric point.
Figure 4a) shows the compound VII docked pose at the binding site with e-pharmacophore sites. b) shows the actives compounds mapped to the e-pharmacophore.
Figure 5a) It shows the enrichment plots for VS methods and b) shows the enrichment plots for data fusion.
It shows the ROC AUC’s of VS methods and data fusion
| E-pharmacophore III | 0.56 | 0.602 | 0.649 | 0.832 |
| ROCS | 0.58 | 0.62 | 0.62 | 0.89 |
| Glide XP | 0.39 | 0.44 | 0.51 | 0.84 |
| Sum score | ||||
| Sum rank | 0.47 | 0.49 | 0.565 | 0.91 |
| Reciprocal rank |
Figure 6It shows the Principal component analysis study of the PknB inhibitors and our predicted compounds. The numbers of the compounds assigned as the positions in the sdf format of Additional file 3.
Figure 7Showing some of the top ranked selected hits binding to the PknB active site.